Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine protects vulnerable infants

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine operates by stimulating the mother’s body’s defences to generate defence proteins, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.

• Nearly 85 per cent coverage when immunised 4 weeks before birth
• Antibodies from the mother passed through placenta protect newborns from day one
• Protection possible with two-week gap before early delivery
• Vaccination in the third trimester still offers meaningful infant protection

Persuasive evidence from current research

The effectiveness of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation undertaken in England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month period, providing robust and representative evidence of the vaccine’s practical effectiveness. The study’s findings have been validated by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The breadth of this investigation provides healthcare professionals and prospective parents with trust in the vaccine’s proven efficacy across different groups and contexts.

The results present a notable picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This clear distinction highlights the vaccine’s vital importance in reducing the risk of serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.

Research approach and coverage

The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospitalisations. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than individual cases or limited subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology assessed actual clinical results rather than laboratory-based settings, providing practical evidence of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.

Learning about RSV and its hazards

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.

The infection produces inflammation deep within the lungs and airways, making it extremely challenging for infected babies to breathe and feed effectively. Parents frequently observe their babies struggling visibly, their chests heaving as they work to get adequate oxygen into their compromised lungs. Whilst most infants improve through supportive care, a limited though important proportion perish from respiratory syncytial virus complications each year, making prevention through vaccination a vital health service imperative for defending the youngest and most vulnerable people in our communities.

• RSV produces inflammation in lungs, causing severe breathing difficulties in babies
• Approximately half of infants catch the virus in their first few months of life
• Symptoms range from mild colds to life-threatening chest infections needing hospital treatment
• Over 20,000 UK babies require serious hospital care for RSV annually
• A small number of babies die from RSV related complications annually in the UK

Take-up rates and specialist advice

Since the RSV vaccine programme commenced in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the optimal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that the timing is essential for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery provides approximately 85% protection, experts encourage women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies via the placenta.

The messaging from health authorities stays clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.

Regional differences in vaccine uptake

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have attained greater immunisation rates among eligible pregnant women, whilst others remain focused to boost understanding and availability of the jab. These geographical variations reflect variations in medical facilities, communication strategies, and local engagement efforts, though the national data demonstrates robust and reliable protection irrespective of geographical location.

• NHS trusts deploying varied communication campaigns to engage with women during pregnancy
• Geographic variations in vaccine uptake rates across England demand focused enhancement
• Community health services adapting programmes to suit local requirements and situations

Real-world impact and parental perspectives

The vaccine’s outstanding effectiveness delivers real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the introduction of this preventative solution, the 80% reduction in admissions equates to thousands of infants shielded from serious illness. Parents no longer face the upsetting situation of seeing their babies gasping for air or difficulty feeding, symptoms that mark serious RSV disease. The vaccine has substantially transformed the picture of neonatal respiratory health, offering expectant mothers a active means to safeguard their most at-risk babies during those critical early months.

For families like that of Malachi, whose acute RSV infection led to profound brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s advocacy for the jab underscores the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to pregnant women during their late pregnancy, transforming what was once an inevitable seasonal threat into a controllable health concern.